Journal of Cutaneous Medicine and Surgery最新文献

筛选
英文 中文
Real-World Strategies for Biologic Dose Escalation and Reduction in Psoriasis and Psoriatic Arthritis: A Systematic Review. 银屑病和银屑病关节炎生物剂量增加和减少的现实世界策略:系统综述。
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-28 DOI: 10.1177/12034754261484596
Orsola Crespi, Isotta Giunipero di Corteranzo, Eleonora Bongiovanni, Umberto Santaniello, Michela Ortoncelli, Pietro Quaglino, Simone Ribero, Luca Mastorino
{"title":"Real-World Strategies for Biologic Dose Escalation and Reduction in Psoriasis and Psoriatic Arthritis: A Systematic Review.","authors":"Orsola Crespi, Isotta Giunipero di Corteranzo, Eleonora Bongiovanni, Umberto Santaniello, Michela Ortoncelli, Pietro Quaglino, Simone Ribero, Luca Mastorino","doi":"10.1177/12034754261484596","DOIUrl":"https://doi.org/10.1177/12034754261484596","url":null,"abstract":"<p><strong>Background: </strong>Biologic therapies have improved treatment of moderate-to-severe psoriasis and psoriatic arthritis. However, real-world dosing often deviates from standard protocols to address suboptimal responses, sustain long-term control, and manage safety or cost. Dose escalation (DE) and dose reduction (DR) strategies are widely used, but data on their frequency, rationale, and outcomes remain fragmented.</p><p><strong>Objective: </strong>To systematically review real-world evidence on DE and DR practices for biologic therapies in moderate-to-severe psoriasis and psoriatic arthritis, focusing on definitions, clinical criteria, and success rates.</p><p><strong>Methods: </strong>A systematic literature review was conducted using PubMed, Scopus, Embase, and the Cochrane Library from January 1, 2005, through December 31, 2024. Eligible studies included adults with moderate-to-severe plaque psoriasis or psoriatic arthritis receiving tumor necrosis factor inhibitors, interleukin-12 (IL-12)/IL-23 inhibitors, IL-17 inhibitors, or IL-23 inhibitors, with reported off-label dose modifications. Data on definitions, timing, clinical criteria, and outcomes were extracted and synthesized.</p><p><strong>Results: </strong>From 2623 records, 63 studies were included. Dose adjustments were defined using varied clinical or timing criteria. DE was most successful when applied moderately and promptly. DR was commonly implemented after stable remission and maintained disease control in 50% to 90% of patients. Adalimumab was the most frequently adjusted biologic. IL-17 and IL-23 inhibitors also showed flexibility. Inconsistent definitions and outcome reporting limited comparability across studies.</p><p><strong>Conclusion: </strong>Dose adjustments are common but inconsistently defined, highlighting the need for standardized definitions and clinical guidance.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261484596"},"PeriodicalIF":2.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sun Protection Behaviours and Melanoma Risk Perception in Canadian Jewish Populations: A Cross-Sectional Survey Study. 加拿大犹太人的防晒行为和黑色素瘤风险认知:一项横断面调查研究。
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-28 DOI: 10.1177/12034754261485274
Raquel Lazarowitz, Santina Conte, Amina Moustaqim-Barrette, Samantha Balass, François Lagacé, Elena Netchiporouk, Ivan V Litvinov
{"title":"Sun Protection Behaviours and Melanoma Risk Perception in Canadian Jewish Populations: A Cross-Sectional Survey Study.","authors":"Raquel Lazarowitz, Santina Conte, Amina Moustaqim-Barrette, Samantha Balass, François Lagacé, Elena Netchiporouk, Ivan V Litvinov","doi":"10.1177/12034754261485274","DOIUrl":"https://doi.org/10.1177/12034754261485274","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261485274"},"PeriodicalIF":2.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Type 1 Diabetes is Associated With Increased Therapeutic Burden in Hidradenitis Suppurativa: A Multicenter Retrospective Matched Case-Control Study. 1型糖尿病与化脓性汗腺炎治疗负担增加相关:一项多中心回顾性匹配病例对照研究
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-28 DOI: 10.1177/12034754261484189
Irene Rivera-Ruiz, Alberto Soto-Moreno, Miguel Mansilla-Polo, Patricia Garbayo-Salmons, Daniel Muñoz-Barba, César Guijarro-Sánchez, Alejandro Molina-Leyva
{"title":"Type 1 Diabetes is Associated With Increased Therapeutic Burden in Hidradenitis Suppurativa: A Multicenter Retrospective Matched Case-Control Study.","authors":"Irene Rivera-Ruiz, Alberto Soto-Moreno, Miguel Mansilla-Polo, Patricia Garbayo-Salmons, Daniel Muñoz-Barba, César Guijarro-Sánchez, Alejandro Molina-Leyva","doi":"10.1177/12034754261484189","DOIUrl":"https://doi.org/10.1177/12034754261484189","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with multiple systemic comorbidities. Although its association with type 2 diabetes is well established, the clinical impact of coexisting type 1 diabetes (T1D) remains poorly defined.</p><p><strong>Objectives: </strong>To compare the clinical characteristics, disease burden, and therapeutic requirements of patients with HS and T1D with matched HS controls.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective matched case-control study across 3 tertiary dermatology departments. Patients with HS and confirmed T1D were matched 1:3 by age, sex, and baseline Hurley stage. Clinical and therapeutic outcomes were assessed over a standardized 48 week follow-up.</p><p><strong>Results: </strong>Twelve patients with HS and T1D and 33 matched controls were included. Baseline disease severity was comparable. During follow-up, patients with HS + T1D had higher mean International Hidradenitis Suppurativa Severity Score System scores (11.95 vs 6.24; <i>P</i> = .01), more draining tunnels (11.0 vs 3.97; <i>P</i> < .01), received more systemic treatments (4.10 vs 3.06; <i>P</i> = .03), and underwent more surgical procedures (1.67 vs 0.67; <i>P</i> < .01).</p><p><strong>Conclusions: </strong>Patients with HS and coexisting T1D may experience a greater inflammatory and therapeutic burden than matched controls. These findings support closer multidisciplinary management and warrant prospective studies to validate T1D as a potential modifier of HS severity.</p><p><strong>Limitations: </strong>Retrospective design and small sample size.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261484189"},"PeriodicalIF":2.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Craniofacial Angiosarcoma. Craniofacial血管肉瘤。
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-24 DOI: 10.1177/12034754261491228
Heli Yang
{"title":"Craniofacial Angiosarcoma.","authors":"Heli Yang","doi":"10.1177/12034754261491228","DOIUrl":"https://doi.org/10.1177/12034754261491228","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261491228"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lupus Vulgaris of the Face. 面部寻常性狼疮。
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-24 DOI: 10.1177/12034754261488370
Sushant Agrawal, Gomathy Sethuraman
{"title":"Lupus Vulgaris of the Face.","authors":"Sushant Agrawal, Gomathy Sethuraman","doi":"10.1177/12034754261488370","DOIUrl":"https://doi.org/10.1177/12034754261488370","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261488370"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blaschkoid Psoriasis.
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-24 DOI: 10.1177/12034754261488358
Yang He, Chunming Li
{"title":"Blaschkoid Psoriasis.","authors":"Yang He, Chunming Li","doi":"10.1177/12034754261488358","DOIUrl":"https://doi.org/10.1177/12034754261488358","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261488358"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proximal Onychomycosis. 近端甲真菌病。
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-24 DOI: 10.1177/12034754261491230
Nuran C Golbasi, Shari R Lipner
{"title":"Proximal Onychomycosis.","authors":"Nuran C Golbasi, Shari R Lipner","doi":"10.1177/12034754261491230","DOIUrl":"https://doi.org/10.1177/12034754261491230","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261491230"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Omalizumab Discontinuation in Chronic Spontaneous Urticaria: Effectiveness and Predictors of Response and Relapse Comparing Abrupt Cessation and Dose Spacing in a Retrospective Real-Life Study. 慢性自发性荨麻疹的Omalizumab停药:在一项回顾性现实研究中比较突然停药和剂量间隔的有效性和反应和复发的预测因素。
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-24 DOI: 10.1177/12034754261484533
Silvia Borriello, Giovanni Cavaliere, Matteo Brizio, Sophie Frassy, Francois Rosset, Nadia Sciamarrelli, Paolo Borrelli, Federica Sardanelli, Astrid Lappi, Pietro Quaglino, Simone Ribero, Luca Mastorino
{"title":"Omalizumab Discontinuation in Chronic Spontaneous Urticaria: Effectiveness and Predictors of Response and Relapse Comparing Abrupt Cessation and Dose Spacing in a Retrospective Real-Life Study.","authors":"Silvia Borriello, Giovanni Cavaliere, Matteo Brizio, Sophie Frassy, Francois Rosset, Nadia Sciamarrelli, Paolo Borrelli, Federica Sardanelli, Astrid Lappi, Pietro Quaglino, Simone Ribero, Luca Mastorino","doi":"10.1177/12034754261484533","DOIUrl":"https://doi.org/10.1177/12034754261484533","url":null,"abstract":"<p><strong>Background: </strong>Omalizumab is a highly effective third-line treatment for chronic spontaneous urticaria (CSU) refractory to antihistamines. However, disease relapse upon cessation is a significant clinical challenge. Real-world evidence comparing different discontinuation strategies is scarce.</p><p><strong>Methods: </strong>This retrospective, multicenter, real-world study evaluated 199 patients with refractory CSU treated with omalizumab (300 mg/month) in the Piedmont-Aosta Valley region. We assessed effectiveness using Urticaria Activity Score (UAS/UAS7) and Dermatology Life Quality Index (DLQI). The primary outcomes were response rates, relapse rates after abrupt discontinuation versus gradual dose spacing, and predictors of these outcomes.</p><p><strong>Results: </strong>Omalizumab demonstrated high effectiveness, achieving a complete response rate of 71% after the first treatment cycle, with drastic reductions in mean UAS7 (from 28.8 to 4.3) and DLQI (from 25.3 to 0.8) by month 4. Abrupt discontinuation resulted in a high relapse rate of 73.7%, with a short median time to recurrence of 2 months. Multivariate analysis found no significant baseline predictors of response. Counterintuitively, a higher baseline UAS7 was associated with a lower risk of relapse. A subgroup of 48 patients, characterized as \"super-responders,\" underwent gradual dose spacing. This group achieved a significantly lower relapse rate of 27.1% after abrupt cessation, without significant symptomatic worsening during tapering.</p><p><strong>Conclusions: </strong>Omalizumab is an effective control therapy for CSU in a real-world setting. Abrupt discontinuation leads to rapid relapse in the majority of patients. Gradual dose spacing represents a promising strategy to prolong remission and reduce drug burden, particularly in patients exhibiting excellent initial therapeutic response.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261484533"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biologic and Systemic Therapies in Pediatric Cutaneous Lupus Erythematosus: An Evidence-Based Review. 儿童皮肤红斑狼疮的生物和全身治疗:基于证据的回顾。
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-24 DOI: 10.1177/12034754261480642
Andy Dongkwun Lee, Darshana Seeburruth, Samantha Bestavros, Ahmed Bagit, Siddhartha Sood, Edgar Akuffo-Addo, Marissa Joseph
{"title":"Biologic and Systemic Therapies in Pediatric Cutaneous Lupus Erythematosus: An Evidence-Based Review.","authors":"Andy Dongkwun Lee, Darshana Seeburruth, Samantha Bestavros, Ahmed Bagit, Siddhartha Sood, Edgar Akuffo-Addo, Marissa Joseph","doi":"10.1177/12034754261480642","DOIUrl":"https://doi.org/10.1177/12034754261480642","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261480642"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lepromatous Leprosy.
IF 2.8 4区 医学
Journal of Cutaneous Medicine and Surgery Pub Date : 2026-09-24 DOI: 10.1177/12034754261487452
Akarsh Agrawal, Ankita Srivastava
{"title":"Lepromatous Leprosy.","authors":"Akarsh Agrawal, Ankita Srivastava","doi":"10.1177/12034754261487452","DOIUrl":"https://doi.org/10.1177/12034754261487452","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261487452"},"PeriodicalIF":2.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书